{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:07:08Z","timestamp":1779210428427,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jilin Provincial Department of Education Science and Technology Research Project","award":["JJKH20210054KJ"],"award-info":[{"award-number":["JJKH20210054KJ"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15884-9","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T03:48:06Z","timestamp":1775447286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of transarterial drug-loaded microsphere chemoembolization against cholangiocarcinoma combined with obstructive jaundice"],"prefix":"10.1186","volume":"26","author":[{"given":"Baoyang","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"15884_CR1","doi-asserted-by":"crossref","unstructured":"Valle JW, Borbath I, Khan S A et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v28\u201337.","DOI":"10.1093\/annonc\/mdw324"},{"key":"15884_CR2","doi-asserted-by":"crossref","unstructured":"Ilyas SI, GoreS GJJG. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215\u201329.","DOI":"10.1053\/j.gastro.2013.10.013"},{"key":"15884_CR3","doi-asserted-by":"crossref","unstructured":"Bridgewater JA, Goodman K A, Kalyan A et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016;36:e194\u2013203.","DOI":"10.1200\/EDBK_160831"},{"issue":"5","key":"15884_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Rev Gastroenterol Hepatol. 2021;15(5):483\u20135.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"15884_CR5","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.21873\/anticanres.14282","volume":"40","author":"A Rizzo","year":"2020","unstructured":"Rizzo A, Ricci AD, Tober N, Nigro MC, Mosca M, Palloni A, Abbati F, Frega G, DE Lorenzo S, Tavolari S, Brandi G. Second-line treatment in advanced biliary tract cancer: today and tomorrow. Anticancer Res. 2020;40(6):3013\u201330.","journal-title":"Anticancer Res"},{"issue":"21","key":"15884_CR6","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis.Cancers. (Basel). 2024;16(21):3689.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"15884_CR7","first-page":"624","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y, Akagunduz B, Kilickap S, De Luca R, Rizzo A. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31(12):624.","journal-title":"Support Care Cancer"},{"issue":"2","key":"15884_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.21873\/invivo.11798","volume":"34","author":"A DE Rizzo","year":"2020","unstructured":"Rizzo A, Frega G, Ricci AD, Palloni A, Abbati F, DE Lorenzo S, Deserti M, Tavolari S, Brandi G. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis. Vivo. 2020;34(2):479\u201388.","journal-title":"Vivo"},{"issue":"3","key":"15884_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","volume":"33","author":"K MALAGARI","year":"2010","unstructured":"Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with beadblock for hepatocellular carcinoma. Cardiovasc Interv Radiol. 2010;33(3):541\u201351.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"1","key":"15884_CR10","first-page":"106","volume":"64","author":"R LENCIONI","year":"2016","unstructured":"Lencioni R, De Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. J. 2016;64(1):106\u201316.","journal-title":"J"},{"issue":"2","key":"15884_CR11","first-page":"243","volume":"16","author":"H WANG","year":"2020","unstructured":"Wang H, Cao C, Wei X, et al. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis of six randomized controlled trials. J. 2020;16(2):243\u20139.","journal-title":"J"},{"issue":"15","key":"15884_CR12","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.7150\/jca.39410","volume":"11","author":"YL ZHOU T Y, ZHOU G H, ZHANG","year":"2020","unstructured":"Zhou T Y, Zhou G H, Zhang YL, et al. Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer. 2020;11(15):4534\u201341.","journal-title":"J Cancer"},{"key":"15884_CR13","doi-asserted-by":"crossref","unstructured":"Gbolahan OB, Schacht MA, Beckley EW et al. Locoregional and systemic therapy for hepatocellular carcinoma. J Gastrointest Oncol. 2017;8(2):215.","DOI":"10.21037\/jgo.2017.03.13"},{"issue":"1","key":"15884_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5114\/ceh.2022.114190","volume":"8","author":"E ZEREM","year":"2022","unstructured":"ZEREM E, IMSIROVIC B, KUNOSIC S. Percutaneous biliary drainage for obstructive jaundice in patients with inoperable, malignant biliary obstruction. Clin Exp Hepatol. 2022;8(1):70\u20137.","journal-title":"Clin Exp Hepatol"},{"issue":"1","key":"15884_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.aat.2014.03.002","volume":"52","author":"L WANG","year":"2014","unstructured":"WANG L, YU W F. Obstructive jaundice and perioperative management. Acta Anaesthesiologica Taiwanica. 2014;52(1):22\u20139.","journal-title":"Acta Anaesthesiologica Taiwanica [J]"},{"key":"15884_CR16","doi-asserted-by":"crossref","unstructured":"Heimbach J K, Kulik L M, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","DOI":"10.1002\/hep.29086"},{"key":"15884_CR17","doi-asserted-by":"crossref","unstructured":"Cremen S, Kelly M E, Gallagher T K J F I, O. The role of neo-adjuvant therapy in cholangiocarcinoma: a systematic review. Front Oncol. 2022;12:975136.","DOI":"10.3389\/fonc.2022.975136"},{"key":"15884_CR18","doi-asserted-by":"crossref","unstructured":"Salem R, Lewandowski R J, Mulcahy M F et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52\u201364.","DOI":"10.1053\/j.gastro.2009.09.006"},{"key":"15884_CR19","doi-asserted-by":"crossref","unstructured":"Kalva S P, Pectasides M, Yeddula K et al. Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24(2):257\u201365.","DOI":"10.1016\/j.jvir.2012.10.021"},{"key":"15884_CR20","first-page":"143","volume":"39","author":"U CILLO","year":"2019","unstructured":"Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. J. 2019;39:143\u201355.","journal-title":"J"},{"key":"15884_CR21","doi-asserted-by":"crossref","unstructured":"Kim RD, Alese OB Chungv et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888\u201394.","DOI":"10.1001\/jamaoncol.2020.0930"},{"key":"15884_CR22","doi-asserted-by":"crossref","unstructured":"Mossner J J C Wwiedmannm, D T. Molecular targeted therapy of biliary tract cancer-results of the first clinical studies. Curr Drug Targets. 2010;11(7):834\u201350.","DOI":"10.2174\/138945010791320818"},{"key":"15884_CR23","doi-asserted-by":"crossref","unstructured":"Lammer J, Malagari K, Vogl T et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41\u201352.","DOI":"10.1007\/s00270-009-9711-7"},{"key":"15884_CR24","doi-asserted-by":"crossref","unstructured":"Golfieri R, Giampalma E, Renzulli M et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255\u201364.","DOI":"10.1038\/bjc.2014.199"},{"key":"15884_CR25","first-page":"1119","volume":"35","author":"K MALAGARI","year":"2012","unstructured":"MALAGARI K, POMONI M, MOSCHOURIS H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. J. 2012;35:1119\u201328.","journal-title":"J"},{"key":"15884_CR26","doi-asserted-by":"crossref","unstructured":"Vogl T J, Naguib N N, Nour-eldin N-E A et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72(3):505\u201316.","DOI":"10.1016\/j.ejrad.2008.08.007"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15884-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15884-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:22:34Z","timestamp":1779207754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15884-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15884"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15884-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the ethical guidelines of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of The Affiliated Hospital of Bei-Hua University. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"632"}}